EU/3/17/1841

About

On 27 February 2017, orphan designation (EU/3/17/1841) was granted by the European Commission to Consejo Superior de Investigaciones Cientificas (CSIC), Spain, for propranolol hydrochloride for the treatment of von Hippel-Lindau disease.

Key facts

Active substance
propranolol hydrochloride
Disease / condition
Treatment of von Hippel-Lindau disease
Date of decision
27/02/2017
Outcome
Positive
Orphan decision number
EU/3/17/1841

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Consejo Superior de Investigaciones Cientificas (CSIC)
C/ Serrano 142
28006 Madrid
Spain
Telephone: +34 91 568 15 31
E-mail: vatc@csic.es

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating